Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 23 04:00PM ET
0.5426
Dollar change
+0.0261
Percentage change
5.05
%
IndexRUT P/E- EPS (ttm)-0.67 Insider Own17.48% Shs Outstand45.55M Perf Week-1.95%
Market Cap27.46M Forward P/E- EPS next Y-0.90 Insider Trans1.91% Shs Float41.76M Perf Month-52.40%
Income-27.26M PEG- EPS next Q-0.23 Inst Own22.52% Short Float12.50% Perf Quarter-67.12%
Sales0.00M P/S- EPS this Y-34.47% Inst Trans-28.80% Short Ratio4.37 Perf Half Y-58.26%
Book/sh0.20 P/B2.75 EPS next Y-1.17% ROA-91.15% Short Interest5.22M Perf Year-88.93%
Cash/sh0.29 P/C1.85 EPS next 5Y- ROE-207.83% 52W Range0.50 - 5.85 Perf YTD-73.91%
Dividend Est.- P/FCF- EPS past 5Y18.26% ROI-141.62% 52W High-90.72% Beta1.79
Dividend TTM- Quick Ratio1.71 Sales past 5Y100.00% Gross Margin-28100.77% 52W Low8.30% ATR (14)0.10
Dividend Ex-Date- Current Ratio1.73 EPS Y/Y TTM19.42% Oper. Margin-670885.82% RSI (14)27.07 Volatility8.81% 11.89%
Employees57 Debt/Eq1.79 Sales Y/Y TTM-99.99% Profit Margin-719859.94% Recom1.00 Target Price8.25
Option/ShortYes / Yes LT Debt/Eq1.14 EPS Q/Q-5.22% Payout- Rel Volume0.73 Prev Close0.52
Sales Surprise947.33% EPS Surprise-3.63% Sales Q/Q- EarningsMar 18 AMC Avg Volume1.19M Price0.54
SMA20-27.97% SMA50-59.38% SMA200-66.78% Trades Volume876,896 Change5.05%
Date Action Analyst Rating Change Price Target Change
Mar-01-21Initiated Northland Capital Outperform $10
Feb-03-20Downgrade Oppenheimer Outperform → Perform
Apr-09-24 09:29AM
Apr-08-24 07:00AM
Apr-03-24 07:00AM
Mar-27-24 11:28AM
09:57AM
08:50AM Loading…
Mar-19-24 08:50AM
06:41AM
Mar-18-24 08:53PM
05:20PM
04:05PM
Mar-13-24 07:00AM
Mar-11-24 07:00AM
Mar-05-24 12:59PM
08:00AM
Mar-04-24 06:21PM
06:06PM Loading…
06:06PM
Feb-13-24 07:00AM
Jan-26-24 09:22AM
Jan-16-24 07:00AM
Dec-15-23 08:17AM
Nov-14-23 10:38AM
Nov-13-23 04:05PM
Nov-06-23 08:00AM
Nov-02-23 07:00AM
Oct-30-23 03:52PM
07:00AM
Oct-09-23 07:00AM
Sep-21-23 08:00AM
Sep-07-23 08:00AM
Aug-24-23 06:47PM
06:00AM Loading…
Aug-16-23 06:00AM
Aug-14-23 09:05AM
Aug-11-23 06:08AM
Aug-10-23 04:05PM
Aug-09-23 08:00AM
Aug-07-23 08:00AM
Aug-03-23 08:00AM
Jun-26-23 08:00AM
Jun-06-23 09:00AM
Jun-01-23 08:00AM
May-12-23 06:04AM
May-11-23 04:05PM
May-08-23 04:39PM
08:17AM
08:02AM
08:00AM
02:32AM
May-04-23 08:00AM
Apr-24-23 08:00AM
Apr-05-23 07:46PM
Mar-30-23 04:05PM
Mar-23-23 08:00AM
Feb-28-23 04:05PM
Feb-22-23 06:08AM
Feb-15-23 09:51AM
Jan-12-23 12:47PM
08:00AM
Dec-20-22 08:00AM
Dec-13-22 08:00AM
Dec-08-22 08:00AM
Nov-29-22 08:00AM
Nov-23-22 04:05PM
Nov-13-22 07:04AM
Nov-10-22 04:05PM
Nov-03-22 08:00AM
Oct-21-22 08:00AM
Oct-20-22 08:00AM
Oct-05-22 02:50PM
Sep-30-22 08:00AM
Sep-07-22 08:00AM
Sep-06-22 08:00AM
Aug-10-22 04:05PM
Aug-04-22 08:00AM
Jul-27-22 08:00AM
Jul-18-22 08:00AM
Jul-07-22 08:00AM
Jul-06-22 08:00AM
Jun-29-22 08:53AM
Jun-09-22 10:09AM
08:00AM
Jun-07-22 08:00AM
May-15-22 08:06AM
May-12-22 04:05PM
May-05-22 08:00AM
Apr-20-22 08:00AM
Apr-19-22 08:00AM
Apr-03-22 01:46PM
Mar-31-22 01:17PM
Mar-28-22 04:05PM
Mar-21-22 08:00AM
Mar-15-22 08:00AM
Mar-04-22 09:07AM
07:00AM
Feb-13-22 06:29AM
Feb-08-22 08:00AM
Feb-07-22 08:30AM
Dec-10-21 05:46AM
Nov-17-21 12:00PM
Nov-10-21 06:45PM
04:05PM
Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression, and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Grant Stuart M.10% OwnerMar 28 '24Buy0.98100,00098,0005,430,715Mar 28 03:50 PM
Grant Stuart M.10% OwnerMar 19 '24Buy1.2350,00061,5005,330,715Mar 20 05:44 PM
Grant Stuart M.10% OwnerMar 08 '24Buy1.5810,71716,9115,280,715Mar 11 08:11 AM
Rowe Michael MChief Executive OfficerDec 04 '23Buy1.364,8906,65032,927Dec 05 04:54 PM
Strahlman Ellen RDirectorSep 29 '23Buy1.684,8208,09875,113Oct 02 10:04 AM
Rowe Michael MChief Executive OfficerSep 19 '23Buy1.661,4002,32428,037Sep 19 05:17 PM
Rowe Michael MChief Executive OfficerSep 15 '23Buy1.751,1371,99026,637Sep 19 05:17 PM
Grant Stuart M.10% OwnerAug 17 '23Buy1.8730,00056,1005,269,998Aug 17 03:16 PM
Grant Stuart M.10% OwnerAug 16 '23Buy1.9145,00085,8155,239,998Aug 17 03:16 PM
GANDOLFO JOHN PChief Financial OfficerMay 31 '23Buy2.792,0005,5808,000May 31 06:31 PM
MATHER CHARLES E IVDirectorMay 26 '23Buy2.493,0007,47077,544May 30 10:13 AM
Kern BrenChief Operating OfficerMay 26 '23Buy2.732,5006,8252,500May 31 10:48 AM
Grant Stuart M.10% OwnerMay 25 '23Buy2.6588,247233,8555,194,998May 26 12:55 PM
Strahlman Ellen RDirectorMay 23 '23Buy3.1010,00030,97653,052May 25 04:45 PM
Rowe Michael MChief Executive OfficerMay 01 '23Option Exercise2.7210,00027,20025,500May 01 08:47 PM
Ianchulev TsontchoDirectorMay 01 '23Sale5.5090,000495,000331,211May 02 07:38 PM
Ianchulev TsontchoDirectorApr 27 '23Sale5.0060,000300,000421,211May 01 12:43 PM